Algorae Pharmaceuticals (ASX:1AI) has announced that it has executed an agreement with Torrent Pharmaceuticals to commercialise two prescription molecules in Australia and New Zealand.
Under the deal, Algorae will pursue a phased commercialisation strategy. Phase one will target products supported by existing regulatory registrations in Australia and New Zealand, including cloned registrations where applicable, enabling earlier market entry once approvals are received and launch readiness is achieved. Phase two will target products that require new regulatory approval.
Th agreement with Torrent also establishes a mechanism for the parties to consider additional molecules from the company's portfolio. Algorae said there is no current commitment to the number, timing, sequencing or commercial terms of any additional molecules.
Responsibility for product development and GMP-compliant manufacturing sits with Torrent. Regulatory pathways and timelines will be determined on a molecule-by-molecule basis. Algorae, through its wholly owned subsidiary AlgoraeRx, is expected to lead commercial activities in Australia and New Zealand, including market access pricing and reimbursement, sales distribution and commercial execution, subject to relevant approvals and product availability.
Commercial terms of the agreement remain confidential. The company said it will update shareholders on the timing of submissions, anticipated launch windows, and expected revenue contribution as the phased commercialisation program advances.
Torrent is a specialty-focused company with extensive global reach, eight manufacturing facilities, and significant R&D capability.
Algorae positioned the agreement with Torrent within its broader business as an AI-enabled pharmaceutical development company that uses its proprietary platform, AlgoraeOS, to identify synergistic drug combinations and accelerate their translation into the clinic.